01—Abstract
Summary
Summary of the 8-K filed November 14, 2022. Cited figures are marked; the original filing is the authoritative source.
Altria Group, Inc. (MO) has filed an 8-K detailing the preliminary approval of a settlement for a shareholder derivative lawsuit.
This lawsuit, which included claims of breach of fiduciary duty, was related to Altria's past investment in JUUL Labs, Inc. (JLI). The preliminary approval, granted by the U.S. District Court for the Eastern District of Virginia on October 26, 2022, signifies a potential resolution to these long-standing legal proceedings.
Investors should note that this is a preliminary step, and the settlement is subject to final court approval. The company is proceeding with the necessary notifications to shareholders and the SEC, including publishing summaries of the settlement in The Wall Street Journal and on its investor relations website.
02—Key points
Key Highlights
- Preliminary approval granted for a settlement in a shareholder derivative action concerning Altria's investment in JUUL Labs, Inc.
- The lawsuit alleged breach of fiduciary duty claims against certain current and former directors and officers.
- The settlement resolves claims related to both the Federal Action and related Virginia state court actions.
- Altria is fulfilling requirements to notify shareholders and the SEC about the proposed settlement.
- Details of the settlement and related notices will be published on Altria's website and in The Wall Street Journal.
- This filing marks a significant step towards resolving past litigation related to the JUUL investment.
03—Questions
Frequently Asked Questions
What is the main event reported in this 8-K filing?
The main event is the preliminary approval granted by a U.S. District Court for a settlement in a shareholder derivative lawsuit. This lawsuit primarily concerned Altria's investment in JUUL Labs, Inc. and alleged breach of fiduciary duty claims.
Does this mean the lawsuit is fully resolved?
No, this is a preliminary approval. The settlement is still subject to final court approval. Altria is now proceeding with the required notices to shareholders and the SEC as part of the process leading to final approval.
What are the implications of this settlement for Altria's investors?
This settlement offers a path to resolve a significant legal overhang related to Altria's past investment in JUUL. Investors can view this as a positive step towards closure on litigation that has been ongoing. However, the final terms and financial impact will be clearer upon final court approval.
Where can I find more information about the settlement?
Altria is publishing a summary of the Notice of Pendency and Proposed Settlement of Derivative Actions in The Wall Street Journal and on its investor relations website at www.altria.com/shareholdersettlement. The full Stipulation and Notice are also filed with the SEC as exhibits.
04—Continue